Tim Smith

This analysis of current testing patterns in the US suggests a need for future studies to explore the rationale used to determine such testing decisions.

In this feature, we acknowledge the impact of the 1964 Surgeon General report, its subsequent effect on public health, and present-day hurdles to optimized public health efforts through the eyes of our editorial advisory board members and other leading experts.

While this research did culminate in strong evidence regarding weight loss and its effects on lung airway responses, the precise mechanism for this phenomenon remains unknown.

This new research may require additional follow up studies on potential harms, as 63% of those in this study’s electronic cigarette arm continue to use the product at 6 months.

In this segment of Lungcast, guest Sue Padernacht went further into the topic of mental health and burnout among clinicians, highlighting some ways to address the situation.

These data represent a significant step toward finding a causal connection for drug-induced alopecia, though further controlled studies may be necessary to isolate certain variables.

This segment of Lungcast guest Sue Padernacht’s discussion involved the very real topic of burnout among clinicians, as well as defining the differences between stress and burnout.

In this discussion, Soung discusses the VISIBLE study results on guselkumab and its design for individuals of diverse skin tones.

In this analysis, it is suggested that fetal growth trajectories require levels of oxygen promoted by the intake of maternal iron and hemoglobin.

These data were the results of the secondary analysis of the Ritux 3 study, as the treatment’s short-term efficacy and safety had been confirmed previously.

This study contributes to existing climate change data by exploring climatic hazards and their relationship with atopic dermatitis, in addition to highlighting research gaps and future predictions.

This research sheds light on increasing concerns related to maternal COVID-19 infection and its impact on neonates.

These data also showed that basophil activation test can be a particularly precise biomarker of allergy compared to tolerance among children who are egg-allergic children.

This research points to the notion that omalizumab may help individuals in more ways than a reduction of their sinonasal symptoms.

This research into EDS-FLU is significant, as there remain no medications approved by the FDA for chronic rhinosinusitis without nasal polyps.

These data were announced by Johnson & Johnson this week and show several encouraging findings regarding guselkumab’s use among patients of different skin types.

These data suggest the promise of morphine for cough among those with idiopathic pulmonary fibrosis, though longer term research may be necessary.

This study and its development of the Prurigo Control Test represents the first of its kind to assess chronic prurigo disease control.

This interview segment with Bhatia featured a discussion on addressing both unmet needs and lack of awareness among patients with actinic keratosis.

Bhatia discussed some of the major takeaways from his Winter Clinical presentation titled ‘What's New and Hot in AK Management.’

In this segment of Porter’s interview, she delves further into the phase 2 findings on lutikizumab and discusses any adverse events and future research.

These data indicate that e-cigarettes and nicotine patches were found not to negatively impact pregnant smokers in a significant way, though further study may be valuable.

In this interview, Porter describes some new and encouraging phase 2 data on lutikizumab treatment for patients with HS who had failed anti-TNF therapy.

The updated labeling for dupilumab’s use resulted from the first phase 3 trial assessing a biologic within this subgroup of eczema patients.

In this interview, Del Rosso spoke on takeaways from his conference talk ‘What's New in the Medicine Chest? Acne, Rosacea, Actinic Keratoses, Psoriasis, Urticaria and Other Common Dermatoses.’

During this segment of his interview, Eingun James Song, MD, spoke about upcoming treatments for psoriasis and personalizing care for patients.

These data, presented at the Winter Clinical conference, showed that roflumilast cream 0.15% led to positive results for patients with eczema.

In this subgroup analysis data shown at Winter Clinical, findings indicated IGA success with topical roflumilast foam among seborrheic dermatitis patients.

In this discussion with E. James Song, MD, several unique clinical pearls for those in dermatology were described and had been drawn from Song’s Winter Clinical presentation.

The factors highlighted in this analysis may help dermatologists to better understand the concerns, misconceptions, and perceived risks reported by patients with HS.